Skip to main content Accessibility help
×
Home

Regional HmPAO SPECT and CT Measurements in the Diagnosis of Alzheimer's Disease

  • A. Mattman (a1), H. Feldman (a2), B. Forste (a3), D. Li (a3), I. Szasz (a4), B.L. Beattie (a5) and M. Schulzer (a6)...

Abstract:

Background:

This study investigated the hypothesis that the combination of regional CT brain atrophy measurements and semiquantitative SPECT regional blood flow ratios could produce a diagnostic test for Alzheimer's disease (AD) with an accuracy comparable to that achieved with the present clinical gold standard of the NINCDS-ADRDA criteria.

Methods:

Single proton emission computed tomography (SPECT) and CT head scans were performed on 122 subjects referred an UBC Alzheimer clinic and diagnosed as either ‘not demented’ (ND-37) or ‘possible/probable AD’ (AD-85) by the NINCDS-ADRDA criteria. Stepwise discriminant analysis (SDA) was performed on the bilateral SPECT regions of interest and compared to bilateral CT qualitative/quantitative assessment in the frontal, parietal and temporal lobes to determine which were most accurate at ND/AD distinction. Receiver operating curves (ROC) were then constructed for these variables individually and for their combined discriminant function.

Results:

The left temporal qualitative cortical atrophy score (CT) and left temporal perfusion ratio (SPECT) were selected in the SDA. The combined discriminant function was more specific at AD/ND distinction than either of CT or SPECT alone. The accuracy of AD/ND distinction with the combined discriminant function was below that achieved by clinical diagnosis according to the NINCDS-ADRDA criteria and was not significantly different from that achieved with SPECT or CT alone as defined by ROC curve analysis.

Conclusion:

The measurements of left temporal cortical atrophy and regional cerebral blood flow were most indicative of AD; however they lacked the sensitivity and specificity to recommend their use as a diagnostic test for AD.

RÉSUMÉ: Introduction et objectifs:

Dans cette étude nous évaluons l'hypothèse selon laquelle l'association de mesures de l'atrophie cérébrale régionale par CT scan et de rapports de débits sanguins régionaux obtenus par SPECT pourrait constituer un test diagnostique de la maladie d'Alzheimer (MA) d'une précision comparable à celle des critères de l'étalon or actuel, le NINCDS-ADRDA.

Méthodes:

122 patients référés à la clinique d'Alzheimer de l'Université de la Colombie-Britannique ont subi un scan cérébral par SPECT et par CT, et on les a classifiés comme non déments (ND-37) ou MA possible/probable (MA-85) selon les critères du NINCDS-ADRDA. Nous avons effectué une analyse factorielle discriminante pas à pas (ADP) sur les données des régions d'intérêt obtenues par SPECT bilatéral et nous l'avons comparée à l'évaluation qualitative/quantitative des lobes pariétaux et temporaux bilatéraux obtenue par CT afin de déterminer quelle méthode d'investigation était plus fiable pour distinguer les patients ND des MA. Des courbes ROC ont ensuite été générées individuellement pour ces variables et pour leur fonction discriminante combinée.

Résultats:

La cote d'atrophie corticale qualitative du lobe temporal gauche (CT) et le taux de perfusion du lobe temporal gauche (SPECT) ont été sélectionnés à l'ADP. La fonction discriminante combinée était plus spécifique pour distinguer la MA de la ND que le CT ou le SPECT seul. La précision de la distinction MA/ND au moyen de la fonction discriminante comtinée état inférieure à celle obtenue par le diagnostic clinique selon les critères du NINCDS-ADRDA et n'était pas signi-ficativement différente de celle obtenue par le SPECT ou le CT seul, selon l'analyse de courbe ROC.

Conclusions:

Les mesures de l'atrophie corticale du lobe temporal gauche et du débit sanguin cérébral régional étaient les meilleurs marqueurs de la MA; cependant, ils n'ont pas une sensibilité et une spécificité suffisante pour recommander leur utilisation comme épreuves diagnostiques de la MA.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Regional HmPAO SPECT and CT Measurements in the Diagnosis of Alzheimer's Disease
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Regional HmPAO SPECT and CT Measurements in the Diagnosis of Alzheimer's Disease
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Regional HmPAO SPECT and CT Measurements in the Diagnosis of Alzheimer's Disease
      Available formats
      ×

Copyright

Corresponding author

Division of Neurology, Vancouver Hospital and HSC-UBC Site, S192-2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2B5

References

Hide All
1. Foster, NL, Chase, TN, Mansi, L, Brooks, R, Fedio, P. Cortical abnormalities in Alzheimer’s disease. Ann Neurol 1984; 16: 649654.
2. Friedland, RP, Budinger, TF, Ganz, E et al. Regional cerebral metabolic alternations in dementia of the Alzheimer type: positron emission tomography with (18F)fluorodeoxyglucose. J Comput Assist Tomogr 1983; 7(4): 590598.
3. Cutler, NR, Haxby, JV, Duara, R et al. Clinical history, brain metabolism, and neuropsychological function in Alzheimer’s disease. Ann Neurol 1985; 18: 298309.
4. McGeer, PL, Kamo, H, Harrop, R, et al. Positron emission tomography in patients with clinically diagnosed Alzheimer’s disease. Can Med Assoc J 1986; 134: 597607.
5. Neary, D, Snowden, JS, Shields, RA, Burjan, AWI, Northen, B Single photon emission tomography using 99mTc-HM-PAO in the investigation of dementia. J Neurol Neurosurg Psychiatry 1987; 50: 11011109.
6. Gemmell, HG, Sharp, PF, Besson, JAO et al. Differential diagnosis in dementia using the cerebral blood flow agent 99mTc HM-PAO: a SPECT study. J Comput Assist Tomogr 1987; 11(3): 398402.
7. Perani, D, Di Piero, V, Vallar, G, Cappa, S, Messa, C. Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer’s disease. J Nucl Med 1988; 29: 15071514.
8. Jagust, WJ, Budinger, TF, Reed, BR The diagnosis of dementia with single photon emission computed tomography. Arch Neurol 1987; 44: 258262.
9. Pearlson, GD, Harris, GJ, Powers, RE et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer’s disease. Arch Gen Psychiatry 1992; 49(5): 402408.
10. Bonte, FJ, Ross, ED, Chehabi, HH, Devous, MD SPECT study of regional cerebral blood flow in Alzheimer disease. J Comput Assist Tomogr 1986; 10(4): 579583.
11. Johnson, KA, Mueller, ST, Walshe, TM, English, RJ, Holman, BL Cerebral perfusion imaging in Alzheimer’s disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol 1987; 44: 165168.
12. Pizzolato, G, Dam, M, Borsato, N, et al. [99mTc]-HM-PAO SPECT in Parkinson’s disease. J Cereb Blood Flow Metab 1988; 8: S101–S108.
13. Spampinato, U, Habert, MO, Mas, JL et al. (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson’s disease: a comparison with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1991; 54: 787792.
14. Launes, J, Sulkava, R, Erkinjuntti, T et al. 99TcM-HMPAO SPECT in suspected dementia. Nucl Med Commun 1991; 12: 757765.
15. Duara, R, Grady, C, Haxby, J et al. Positron emission tomography in Alzheimer’s disease. Neurology 1986; 36: 879887.
16. Haxby, JV, Grady, CL, Duara, R, Cutler, NR, Rapoport, SI. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer’s disease. J Cereb Blood Flow Metab 1985; 5(2): 193200.
17. Haxby, JV, Grady, CL, Duara, R et al. Neocortical metabolic abnormalities precede non-memory cognitive defects in early Alzheimer’s type dementia. Arch Neurol 1986; 43: 882885.
18. O’Brien, JT, Eagger, S, Syed, GMS, Sahakian, BJ, Levy, R A study of regional cerebral blood flow and cognitive performance in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1992; 55: 11821187.
19. Karbe, H, Kertesz, A, Davis, J et al. Quantification of functional deficit in Alzheimer’s disease using a computer–assisted mapping program for 99mTc-HMPAO SPECT. Neuroradiology 1994; 36: 16.
20. Jobst, KA, Smith, AD, Barker, CS et al. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1992; 55(3): 190194.
21. Liu, HC, Liu, RS, Lin, KN et al. Single photon emission computed tomography using 99Tcm-HMPAO in Alzheimer’s disease. Nucl Med Commun 1992; 13: 535541.
22. Claus, JJ, van Harskamp, F, Breteler, MMB et al. The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer’s disease: a population-based study. Neurology 1994; 44: 454461.
23. Hughes, CP, Gado, M CT and aging of the brain. Radiology 1981; 139: 391396.
24. LeMay, M, Stafford, JL, Sandor, T et al. Statistical assessment of perceptual CT scan ratings in patients with Alzheimer type dementia. J Comput Assist Tomogr 1986; 10(5): 802809.
25. Golomb, J, de Leon, MJ, Kluger, A et al. Hippocampal atrophy in normal aging. An association with recent memory impairment. Arch Neurol 1993; 509: 967973.
26. Itoh, M, Hatazawa, J, Miyazawa, H et al. Stability of cerebral blood flow and oxygen metabolism during normal aging. Gerontology 1990; 36(1): 4348.
27. DeCarli, C, Kaye, JA, Horwitz, B, Rapoport, SI Critical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type. Neurology 1990; 40: 872883.
28. Willmer, J, Carruthers, A, Guzman, DA et al. The usefulness of CT scanning in diagnosing dementia of the Alzheimer type. Can J Neurol Sci 1993; 20: 210216.
29. de Leon, MJ, Ferris, SH, George, AE et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer’s disease. J Cereb Blood Flow Metab 1983; 3(3): 391394.
30. Soininen, H, Reinikainen, KJ, Puranen, M, et al. Wide third ventricle correlates with low choline acetyltransferase activity of the neocortex in Alzheimer patients. Alzheimer Dis Assoc Disord 1993; 7(1): 3947.
31. Convit, A, de Leon, MJ, Golomb, J et al. Hippocampal atrophy in early Alzheimer’s disease: anatomic specificity and validation. Psychiatr Q 1993; 64(4): 371387.
32. Tanna, NK, Kohn, MI, Horwich, DN et al. Analysis of brain and cerebrospinal fluid volumes with MR imaging: impact on PET data correction for atrophy. Part II. Aging and Alzheimer dementia. Radiology 1991; 178(1): 123130.
33. Matsuzawa, T, Hishinuma, T, Matsui, H et al. Severe atrophy of amygdala and hippocampus in both Alzheimer’s disease and multi-infarct dementia. Sci Rep Res Inst Tohoku Univ 1990; 37(1–4): 2325.
34. de Leon, MJ, Golomb, J, George, AE et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. Am J Neurolradiol 1993; 14(4): 897906.
35. Jobst, KA, Smith, AD, Szatmari, M et al. Detection in life of confirmed Alzheimer’s disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992; 340(8829): 11791183.
36. George, AE, de Leon, MJ, Stylopoulos, LA et al. CT diagnostic features of Alzheimer disease: importance of the choroidal/hippocampal fissure complex. Am J Neuroradiol 1990; 11: 101107.
37. Kido, DK, Caine, ED, LeMay, M et al. Temporal lobe atrophy in patients with Alzheimer disease: a CT study. Am J Neuroradiol 1989; 10: 551555.
38. Jobst, KA, Hindley, NJ, King, E, Smith, AD The Diagnosis of Alzheimer’s Disease: a Question of Image? J Clin Psychiatry 1994; 55(Suppl 11): 2231.
39. McKhann, G, Drachman, DA, Folstein, M et al. Clinical diagnosis of Alzheimer’s disease — Report of the the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939944.
40. American Psychiatric Association : Diagnostic and statistical manual of mental disorders (DSM III-R) , ed 3, Washington DC, American Psychiatric Association, 1987.
41. Crockett, D, Tuokko, H, Koch, W, Parks, R The assessment of everyday functioning using the Present Functioning Questionnaire and the Functional Rating Scale in elderly samples. Clin Gerontol 1989; 8: 325.
42. Feldman, H, Schulzer, M, Wang, S, Tuokko, H, Beattie, BL The Functional Rating Scale in Alzheimer’s disease assessment: a longitudinal study. In: Iqbal, K, Mortimer, JA, Winblad, B, Wisniewski, HM, eds. Research Advances in Alzheimer’s Disease and Related Disorders. London: John Wiley & Sons, 1995: 235241.
43. Crook, TH, Larrabee, GJ, Youngjohn, JR Diagnosis and assessment of age-associated memory impairment. [Review]. Clin Neuropharm 1990; 13(Suppl 3): S81–S91.
44. Ebly, EM, Hogan, DB, Parhad, IM Cognitive Impairment in the nondemented elderly: results from the Canadian Study of Health and Aging. Arch Neurol 1995; 52: 612619.
45. Hurwitz, TA, Ammann, W, Chu, D et al. Single photon emission computed tomography using 99m Tc-HM-PAO in the routine evaluation of Alzheimer’s disease. Can J Neurol Sci 1991; 18: 5962.
46. Gomori, JM, Steiner, I, Melamed, E, Cooper, G The assessment of changes in brain volume using combined linear measurements. A CT-scan study. Neuroradiology 1984; 26: 2124.
47. Brinkman, SD, Sarwar, M, Levin, HS, Morris, HH Quantitative indexes of computed tomography in dementia and normal aging. Radiology 1981; 138: 8992.
48. Soininen, H, Puranen, M, Riekkinen, PJ Computed tomography findings in senile dementia and normal aging. J Neurol Neurosurg Psychiatry 1995; 45: 5054.
49. Van den Bossche, B, Maes, M, Brussaard, C et al. Computed tomography of the brain in unipolar depression. J Affective Disord 1991; 21(1): 6774.
50. Aylward, EH, Karagiozis, H, Pearlson, G, Folstein, MF Suprasellar cistern measures as a reflection of dementia in Alzheimer’s disease but not Huntington’s disease. J Psychiatr Res 1991; 25(1–2): 3147.
51. Hirashima, Y, Shindo, K, Endo, S Measurement of the area of the anterior horn of the right lateral ventricle for the diagnosis of brain atrophy by CT. Neuroradiology 1983; 25: 2327.
52. Steiger, JH Tests for comparing elements of a correlation matrix. Psychol Bull 1980; 87(2): 245251.
53. Morris, JC, McKeel, DW, Fulling, K, Torack, RM, Berg, L Validation of Clinical Diagnostic Criteria for Alzheimer’s Disease. Ann Neurol 1988; 24: 1722.
54. Tierney, MC, Fisher, RH, Lewis, AJ et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer’s disease: a clinicopathologic study of 57 cases. Neurology 1988; 38: 359364.
55. Blacker, D, Albert, MS, Bassett, SS et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer’s disease. Arch Neurol 1994; 51: 11981204.
56. Holman, BL, Johnson, KA, Gerada, B, Carvalho, PA, Satlin, A The scintigraphic appearance of Alzheimer’s disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med 1992; 33: 181185.
57. Jagust, WJ, Johnson, KA, Holman, BL SPECT Perfusion Imaging in the Diagnosis of Dementia. J Neuroimaging 1995; 5(Suppl 1): s45–s52.
58. Johnson, KA, Kijewski, MF, Becker, JA et al. Quantitative brain SPECT in Alzheimer’s disease and normal aging. J Nucl Med 1993; 34(11): 20442048.
59. Tuokko, H, Vernon-Wilkinson, RV, Weir, J, Beattie, BL Cued recall and the early identification of dementia. J Clin Exp Neuropsychol 1991; 13: 871879.
60. Petersen, RC, Smith, GE, Ivnik, RJ, Kokmen, E, Tangalos, EG Memory function in very early Alzheimer’s disease. Neurology 1994; 44: 867872.
61. Chawluk, JB, Dann, R, Alavi, A et al. The effect of focal cerebral atrophy in positron emission tomographic studies of aging and dementia. Nucl Med Biol 1990; 17: 797804.
62. Eberling, JL, Jagust, WJ, Reed, BR, Baker, MG Reduced temporal lobe blood flow in Alzheimer’s disease. Neurobiol Aging 1992; 13: 483491.
63. Brun, A, Englund, E Regional pattern of degeneration in Alzheimer’s disease: neuronal loss and histopathological grading. Histopathology 1981; 5: 549564.
64. Friedland, RP, Brun, A, Budinger, TF Pathological and positron emission tomographic correlations in Alzheimer’s disease. Lancet 1985; 1: 228.

Regional HmPAO SPECT and CT Measurements in the Diagnosis of Alzheimer's Disease

  • A. Mattman (a1), H. Feldman (a2), B. Forste (a3), D. Li (a3), I. Szasz (a4), B.L. Beattie (a5) and M. Schulzer (a6)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed